Evolution of drug resistance: Insight on TEM β-lactamases structure and activity and β-Lactam antibiotics

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 2, 2014, Pages 111-122

  Pimenta, A C ^a,b,c   Fernandes, R ^b,c   Moreira, I S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c Centro de Farmacologia e Biopatologia Química U38 FCT   (Portugal)

Author keywords

Antibiotics; CMT; ESBL; IRT; TEM; lactamases

Indexed keywords

ALANINE; AMOXICILLIN PLUS CLAVULANIC ACID; ARGININE; ASPARAGINE; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; BETA LACTAMASE TEM 30; BETA LACTAMASE TEM 32; BETA LACTAMASE TEM 34; BETA LACTAMASE TEM 64; BETA LACTAMASE TEM 69; BETA LACTAMASE TEM 76; CARBAPENEM; CARBAPENEMASE; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; GLUTAMINE; GLYCINE; METHIONINE; PENICILLIN BINDING PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; SERINE; SULTAMICILLIN; TEM BETA LACTAMASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STRUCTURE; HUMAN; MUTATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84894095572     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666140123145809     Document Type: Article

References (80)

1. Kong, K.-F.; Schneper, L.; Mathee, K., Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS, 2010, 118, (1), 1-36.
2. Chen, Y.; Zhang, W.; Shi, Q.; Hesek, D.; Lee, M.; Mobashery, S.; Shoichet, B.K., Crystal Structures of Penicillin-Binding Protein 6 from Escherichia coli. J. Am. Chem. Soc., 2009, 131, (40), 14345-14354.
3. Bradford, P.A., Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev., 2001, 14, (4), 933-951.
4. Salverda, M.L.; De Visser, J.A.; Barlow, M., Natural evolution of TEM-1 β-lactamase: experimental reconstruction and clinical relevance. FEMS Microbiol. Rev., 2010, 34, (6), 1015-1036.
5. Bush, K., The evolution of beta-lactamases. Ciba Found Symp, 1997, 207, 152-163; discussion 163-156.
6. Bush, K., β-Lactamases of increasing clinical importance. Curr. Pharm. Des., 1999, 5, (11), 839-845.
7. Fisher, J.F.; Meroueh, S.O.; Mobashery, S., Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity. Chem. Rev., 2005, 105, (2), 395-424.
8. Llarrull, L.I.; Testero, S.A.; Fisher, J.F.; Mobashery, S., The future of the β-lactams. Curr. Opin. Microbiol., 2010, 13, (5), 551-557.
9. Wilke, M.S.; Lovering, A.L.; Strynadka, N.C.J.,β-Lactam antibiotic resistance: a current structural perspective. Curr. Opin. Microbiol., 2005, 8, (5), 525-533.
10. Abraham EP, Fau Chain, E.; Chain, E., An enzyme from bacteria able to destroy penicillin. 1940. (0162-0886 (Print)).
11. Bush, K.; Fisher, J.F. In Annual Review of Microbiology, Vol 65. Gottesman, S.; Harwood, C.S., Eds.; Annual Reviews: Palo Alto, 2011.65, 455-478.
12. Bös, F.; Pleiss, J., Conserved Water Molecules Stabilize the Loop in Class A β-Lactamases. Antimicrob. Agents Chemother., 2008, 52, (3), 1072-1079.
13. Stapleton, P.D.; Shannon, K.P.; French, G.L., Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended spectrum resistance and resistance to beta-lactamase inhibitors. Antimicrob. Agents Chemother., 1999, 43, (8), 1881-1887.
14. Wang, X.; Minasov, G.; Shoichet, B.K., Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol., 2002, 320, (1), 85-95.
15. Coque, T.M.; Baquero, F.; Canton, R., Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro. Surveill., 2008, 13, (47).
16. Bush, K.; Fisher, J.F. In Annual Review of Microbiology. Gottesman, S.; Harwood, C.S., Eds.; Annual Reviews: Palo Alto, 2011, 65, 455-478.
17. Jacoby, G.A.; Munoz-Price, L.S., The new beta-lactamases. N. Engl. J. Med., 2005, 352, (4), 380-391.
18. Canton, R.; Gonzalez-Alba, J.M.; Galan, J.C., CTX-M Enzymes: Origin and Diffusion. Front Microbiol., 2012, 3, 110.
19. Paterson, D.L.; Bonomo, R.A., Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev., 2005, 18, (4), 657-686.
20. Philippon, A.; Arlet, G.; Lagrange, P., Extended spectrum beta-lactamases. Rev. Prat., 1993, 43, (18), 2387-2395.
21. Queenan, A.M.; Bush, K., Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev., 2007, 20, (3), 440-458, table of contents.
22. Canton, R.; Coque, T.M., The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol., 2006, 9, (5), 466-475.
23. Bauernfeind, A.; Grimm, H.; Schweighart, S., A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection, 1990, 18, (5), 294-298.
24. Bauernfeind, A.; Casellas, J.M.; Goldberg, M.; Holley, M.; Jungwirth, R.; Mangold, P.; Rohnisch, T.; Schweighart, S.; Wilhelm, R., A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection, 1992, 20, (3), 158-163.
25. Bonnet, R.; Sampaio, J.L.; Labia, R.; De Champs, C.; Sirot, D.; Chanal, C.; Sirot, J., A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae. Antimicrob. Agents Chemother., 2000, 44, (7), 1936-1942.
26. Sabate, M.; Tarrago, R.; Navarro, F.; Miro, E.; Verges, C.; Barbe, J.; Prats, G., Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing. Antimicrob. Agents Chemother., 2000, 44, (7), 1970-1973.
27. Munday, C.J.; Boyd, D.A.; Brenwald, N.; Miller, M.; Andrews, J.M.; Wise, R.; Mulvey, M.R.; Hawkey, P.M., Molecular and kinetic comparison of the novel extended-spectrum beta-lactamases. Antimicrob. Agents Chemother., 2004, 48, (12), 4829-4834.
28. Bonnet, R., Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother., 2004, 48, (1), 1-14.
29. Rossolini, G.M.; D'Andrea, M.M.; Mugnaioli, C., The spread of CTX-M-type extended-spectrum beta-lactamases. Clin. Microbiol. Infect., 2008, 14 Suppl 1, 33-41.
30. Ripoll, A.; Baquero, F.; Novais, A.; Rodriguez-Dominguez, M.J.; Turrientes, M.C.; Canton, R.; Galan, J.C., In vitro selection of variants resistant to beta-lactams plus beta-lactamase. Antimicrob. Agents Chemother., 2011, 55, (10), 4530-4536.
31. Gazouli, M.; Tzelepi, E.; Sidorenko, S.V.; Tzouvelekis, L.S., Sequence of the gene encoding a plasmid-mediated cefotaxime-hydrolyzing class A. Antimicrob. Agents Chemother., 1998, 42, (5), 1259-1262.
32. Hellinger, W.C.; Brewer, N.S., Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo. Clin. Proc., 1999, 74, (4), 420-434.
33. Rodloff, A.C.; Goldstein, E.J.; Torres, A., Two decades of imipenem therapy. J. Antimicrob. Chemother., 2006, 58, (5), 916-929.
34. Dalhoff, A.; Janjic, N.; Echols, R., Redefining penems. Biochem. Pharmacol., 2006, 71, (7), 1085-1095.
35. Sacha, P.; Ostas, A.; Jaworowska, J.; Wieczorek, P.; Ojdana, D.; Ratajczak, J.; Tryniszewska, E., The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli. Folia Histochem. Cytobiol., 2009, 47, (4), 537-543.
36. Cuzon, G.; Naas, T.; Nordmann, P., KPC carbapenemases: what is at stake in clinical microbiology?. Pathol. Biol. (Paris), 2010, 58, (1), 39-45.
37. Bush, K.; Jacoby, G., Nomenclature of TEM beta-lactamases. J. Antimicrob. Chemother., 1997, 39, (1), 1-3.
38. Bush, K.; Jacoby, G.A., Updated functional classification of beta-lactamases. Antimicrob. Agents Chemother., 2010, 54, (3), 969-976.
39. Ambler, R.P., The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1980, 289, (1036), 321-331.
40. Yigit, H.; Queenan, A.M.; Anderson, G.J.; Domenech-Sanchez, A.; Biddle, J.W.; Steward, C.D.; Alberti, S.; Bush, K.; Tenover, F.C., Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2001, 45, (4), 1151-1161.
41. Wolter, D.J.; Kurpiel, P.M.; Woodford, N.; Palepou, M.F.; Goering, R.V.; Hanson, N.D., Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob. Agents Chemother., 2009, 53, (2), 557-562.
42. Nordmann, P.; Cuzon, G.; Naas, T., The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet. Infect. Dis., 2009, 9, (4), 228-236.
43. Wei, Z.Q.; Du, X.X.; Yu, Y.S.; Shen, P.; Chen, Y.G.; Li, L.J., Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob. Agents Chemother., 2007, 51, (2), 763-765.
44. Petrella, S.; Ziental-Gelus, N.; Mayer, C.; Renard, M.; Jarlier, V.; Sougakoff, W., Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob. Agents Chemother., 2008, 52, (10), 3725-3736.
45. Cuzon, G.; Naas, T.; Demachy, M.C.; Nordmann, P., Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob. Agents Chemother., 2008, 52, (2), 796-797.
46. Bradford, P.A.; Bratu, S.; Urban, C.; Visalli, M.; Mariano, N.; Landman, D.; Rahal, J.J.; Brooks, S.; Cebular, S.; Quale, J., Emergence of Carbapenem-Resistant Klebsiella Species Possessing the Class A Carbapenem-Hydrolyzing KPC-2 and Inhibitor-Resistant TEM-30 β-Lactamases in New York City. Clin. Infect. Diseases, 2004, 39, (1), 55-60.
47. Bratu, S.; Landman, D.; Alam, M.; Tolentino, E.; Quale, J., Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother., 2005, 49, (2), 776-778.
48. Bratu, S.; Tolaney, P.; Karumudi, U.; Quale, J.; Mooty, M.; Nichani, S.; Landman, D., Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother., 2005, 56, (1), 128-132.
49. Bratu, S.; Mooty, M.; Nichani, S.; Landman, D.; Gullans, C.; Pettinato, B.; Karumudi, U.; Tolaney, P.; Quale, J., Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother., 2005, 49, (7), 3018-3020.
50. Bratu, S.; Landman, D.; Haag, R.; Recco, R.; Eramo, A.; Alam, M.; Quale, J., Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med., 2005, 165, (12), 1430-1435.
51. Wood-ford, N.; Tierno, P.M.; Young, K.; Tysall, L.; Palepou, M.F.; Ward, E.; Painter, R.E.; Suber, D.F.; Shungu, D.; Silver, L.L.; Inglima, K.; Kornblum, J.; Livermore, D.M., Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother., 2004, 48, (12), 4793-4799.
52. Stec, B.; Holtz, K.M.; Wojciechowski, C.L.; Kantrowitz, E.R., Structure of the wild-type TEM-1 beta-lactamase at 1.55 A and the mutant enzyme Ser70Ala at 2.1 A suggest the mode of noncovalent catalysis for the mutant enzyme. Acta Crystallogr D. Biol. Crystallogr., 2005, 61, (Pt 8), 1072-1079.
53. Doucet, N.; Savard, P.Y.; Pelletier, J.N.; Gagné, S.M., NMR investigation of Tyr105 mutants in TEM-1 beta-lactamase: dynamics are correlated with function. J. Biol. Chem., 2007, 282, (29), 21448-21459.
54. Fisette, O.; Morin, S.; Savard, P.Y.; Lagüe, P.; Gagné, S.M., TEM-1 backbone dynamics-insights from combined molecular dynamics and nuclear magnetic resonance. Biophys. J., 2010, 98, (4), 637-645.
55. Minasov, G.; Wang, X.; Shoichet, B.K., An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J. Am. Chem. Soc., 2002, 124, (19), 5333-5340.
56. Page, M.G., Extended-spectrum beta-lactamases: structure and kinetic mechanism. Clin. Microbiol. Infect., 2008, 14 Suppl 1, 63-74.
57. Meroueh, S.O.; Roblin, P.; Golemi, D.; Maveyraud, L.; Vakulenko, S.B.; Zhang, Y.; Samama, J.P.; Mobashery, S., Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. J. Am. Chem. Soc., 2002, 124, (32), 9422-9430.
58. Thomas, V.L.; Golemi-Kotra, D.; Kim, C.; Vakulenko, S.B.; Mobashery, S.; Shoichet, B.K., Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry, 2005, 44, (26), 9330-9338.
59. Massova, I.; Kollman, P.A., pKa, MM, and QM studies of mechanisms of β-lactamases and penicillin-binding proteins: Acylation step. J. Comput. Chem., 2002, 23, (16), 1559-1576.
60. Bernstein, F.C.; Koetzle, T.F.; Williams, G.J.; Meyer, E.F.; Brice, M.D.; Rodgers, J.R.; Kennard, O.; Shimanouchi, T.; Tasumi, M., The Protein Data Bank. A computer β-based archival file for macromolecular structures. Eur. J. Biochem., 1977, 80, (2), 319-324.
61. Hermann, J.C.; Pradon, J.; Harvey, J.N.; Mulholland, A.J., High level QM/MM modeling of the formation of the tetrahedral intermediate in the acylation of wild type and K73A mutant TEM-1 class A beta-lactamase. J. Phys. Chem. A., 2009, 113, (43), 11984-11994.
62. Brown, N.G.; Pennington, J.M.; Huang, W.; Ayvaz, T.; Palzkill, T., Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases. J. Mol. Biol., 2010, 404, (5), 832-846.
63. Jacoby, G. β-Lactamase Classification and Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant Enzymes. http://www.lahey.org/Studies/
64. Wang, X.; Minasov, G.; Shoichet, B.K., The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34. J. Biol. Chem., 2002, 277, (35), 32149-32156.
65. Brown, N.G.; Shanker, S.; Prasad, B.V.; Palzkill, T., Structural and biochemical evidence that a TEM-1 beta-lactamase N170G active site mutant acts via substrate-assisted catalysis. J. Biol. Chem., 2009, 284, (48), 33703-33712.
66. Marciano, D.C.; Pennington, J.M.; Wang, X.; Wang, J.; Chen, Y.; Thomas, V.L.; Shoichet, B.K.; Palzkill, T., Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase. J. Mol. Biol., 2008, 384, (1), 151-164.
67. Knox, J.R., Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother., 1995, 39, (12), 2593-2601.
68. Saves, I.; Burlet-Schiltz, O.; Swarén, P.; Lefèvre, F.; Masson, J.M.; Promé, J.C.; Samama, J.P., The asparagine to aspartic acid substitution at position 276 of TEM β-35 and TEM-36 is involved in the beta-lactamase resistance to clavulanic acid. J. Biol. Chem., 1995, 270, (31), 18240-18245.
69. Chaïbi, E.B.; Sirot, D.; Paul, G.; Labia, R., Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother., 1999, 43, (4), 447-458.
70. Swarén, P.; Golemi, D.; Cabantous, S.; Bulychev, A.; Maveyraud, L.; Mobashery, S.; Samama, J.P., X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry, 1999, 38, (30), 9570-9576.
71. Vakulenko, S.; Golemi, D., Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors. Antimicrob. Agents Chemother., 2002, 46, (3), 646-653.
72. Robin, F.; Delmas, J.; Schweitzer, C.; Tournilhac, O.; Lesens, O.; Chanal, C.; Bonnet, R., Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob. Agents Chemother., 2007, 51, (4), 1304-1309.
73. Chaibi, E.B.; Péduzzi, J.; Farzaneh, S.; Barthélémy, M.; Sirot, D.; Labia, R., Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. Biochim. Biophys. Acta, 1998, 1382, (1), 38-46.
74. Jelsch, C.; Mourey, L.; Masson, J.M.; Samama, J.P., Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution. Proteins, 1993, 16, (4), 364-383.
75. Giakkoupi, P.; Hujer, A.M.; Miriagou, V.; Tzelepi, E.; Bonomo, R.A.; Tzouvelekis, L.S., Substitution of Thr for Ala-237 in TEM-17, TEM-12 and TEM-26: alterations in beta-lactam resistance conferred on Escherichia coli. FEMS Microbiol. Lett., 2001, 201, (1), 37-40.
76. Cantu, C.; Palzkill, T., The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics. J. Biol. Chem., 1998, 273, (41), 26603-26609.
77. Blázquez, J.; Negri, M.C.; Morosini, M.I.; Gómez-Gómez, J.M.; Baquero, F., A237T as a modulating mutation in naturally occurring extended-spectrum TEM-type beta-lactamases. Antimicrob. Agents Chemother., 1998, 42, (5), 1042-1044.
78. Labia, R.; Morand, A.; Tiwari, K.; Sirot, J.; Sirot, D.; Petit, A., Interactions of new plasmid-mediated beta-lactamases with third- generation cephalosporins. Rev. Infect. Dis., 1988, 10, (4), 885-891.
79. Venkatachalam, K.V.; Huang, W.; LaRocco, M.; Palzkill, T., Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J. Biol. Chem., 1994, 269, (38), 23444-23450.
80. lmtiaz, U.; Manavathu, E.K.; Mobashery, 5.; Lerner, S.A., Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrob. Agents Chemother., 1994, 38, (5), 1134-1139.